Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BNT162b2 + BNT161
- Development stage
- Phase 2
- Lead developer
- BioNTech
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**BNT162b2 + BNT161** is an investigational mRNA-based combination vaccine developed by BioNTech and Pfizer to prevent both COVID-19 and influenza with a single injection. It encodes the SARS-CoV-2 spike protein (from wild-type and Omicron BA.4/BA.5 sublineages) from BNT162b2 alongside influenza hemagglutinin antigens from BNT161 (covering four WHO-recommended Northern Hemisphere strains). The vaccine leverages lipid nanoparticle-delivered mRNA to induce immune responses against both viruses, received FDA Fast Track Designation in 2022, and entered Phase 1 trials to assess safety, tolerability, and immunogenicity in healthy adults.[1][4]
- Brand names
- Combination COVID-19 & Influenza - BioNTech/PfizermRNA-based combination vaccine - BioNTech/Pfizer
- Other names
- Tozinameran vaccine combination
02
Targets
SARS-CoV-2 spikeACE2 (Angiotensin-converting enzyme 2)HA (Hemagglutinin)
Beyond the preview
Go deeper on BNT162b2 + BNT161.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BNT162b2 + BNT161.